Suppr超能文献

ABCB1 在介导三阴性乳腺癌化疗耐药中的作用。

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.

机构信息

Northern Clinical School, Faculty of Medicine and Health, University of Sydney, NSW, Australia.

Kolling Institute of Medical Research, St Leonards, NSW, Australia.

出版信息

Biosci Rep. 2021 Feb 26;41(2). doi: 10.1042/BSR20204092.

Abstract

Triple-negative breast cancer (TNBC) is a group of breast cancers which neither express hormonal receptors nor human epidermal growth factor receptor. Hence, there is a lack of currently known targeted therapies and the only available line of systemic treatment option is chemotherapy or more recently immune therapy. However, in patients with relapsed disease after adjuvant or neoadjuvant therapy, resistance to chemotherapeutic agents has often developed, which results in poor treatment response. Multidrug resistance (MDR) has emerged as an important mechanism by which TNBCs mediate drug resistance and occurs primarily due to overexpression of ATP-binding cassette (ABC) transporter proteins such as P-glycoprotein (Pgp). Pgp overexpression had been linked to poor outcome, reduced survival rates and chemoresistance in patients. The aim of this mini-review is to provide a topical overview of the recent studies and to generate further interest in this critical research area, with the aim to develop an effective and safe approach for overcoming Pgp-mediated chemoresistance in TNBC.

摘要

三阴性乳腺癌(TNBC)是一组既不表达激素受体也不表达人表皮生长因子受体的乳腺癌。因此,目前缺乏已知的靶向治疗方法,唯一可用的系统治疗选择是化疗或最近的免疫治疗。然而,在接受辅助或新辅助治疗后复发的患者中,经常会出现对化疗药物的耐药性,导致治疗反应不佳。多药耐药(MDR)已成为 TNBC 介导耐药性的重要机制,主要是由于三磷酸腺苷结合盒(ABC)转运蛋白如 P-糖蛋白(Pgp)的过度表达。Pgp 的过度表达与患者的不良预后、生存率降低和化疗耐药性有关。本综述的目的是提供对最近研究的专题概述,并激发对这一关键研究领域的进一步兴趣,旨在为克服 TNBC 中 Pgp 介导的化疗耐药性开发一种有效和安全的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d9/7909869/4b31ce631024/bsr-41-bsr20204092-g1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验